Clinical Value of Fibroblast Growth Factor 19 in Predicting Gastrointestinal Dysfunction in Patients with Sepsis

Overview

Journal Front Nutr

Specialty Nutritional Sciences

Date 2024 Sep 19

PMID 39296513

Authors

Linsai Guan

Feiyao Wang

Jingni Chen

Yanxin Xu

Weixing Zhang

Jianping Zhu

Affiliations

Soon will be listed here.

Abstract

Objective: To assess the potential value of fibroblast growth factor 19 (FGF19) as a predictor of gastrointestinal (GI) dysfunction in patients with sepsis.

Methods: A prospective study was conducted, and 209 patients who were diagnosed with sepsis and admitted to the intensive care unit (ICU) at teaching hospitals in China were enrolled from June 2023 to December 2023. The serum FGF19 level was determined at ICU admission. The differences in serum FGF19 levels between the two groups were compared via the Mann-Whitney U test, and Spearman's correlation coefficient was used to identify the correlations of the FGF19 concentration with other clinical variables and biomarkers. Receiver operating characteristic (ROC) analysis was used to determine the value of FGF19 in predicting GI dysfunction in patients with sepsis.

Results: The total ICU mortality rate was 13.3% (24/180). There was a tendency toward increased ICU mortality in patients with sepsis-associated GI dysfunction compared with patients without GI dysfunction with statistical significance (21.9% vs. 8.6%, = 0.031). Serum FGF19 levels were significantly higher in patients with sepsis-associated GI dysfunction than in patients without GI dysfunction [355.1 (37.2, 2315.4) μg/mL vs. 127.4 (5.7, 944.2) μg/mL, = 0.003]. The results of receiver operating characteristic (ROC) curve analysis revealed that the area under the ROC curve (AUC) for the ability of FGF19 to predict GI dysfunction in patients with sepsis was 0.773 (95% CI 0.712 ~ 0.827), which was greater than the predictive capacity of PCT [AUC = 0.632 (95% CI 0.562 ~ 0.804)].

Conclusion: Serum FGF19 could be considered as a novel predictor or biomarker of GI dysfunction in patients with sepsis.

References

Shi L, Jin L, Huang W . Bile Acids, Intestinal Barrier Dysfunction, and Related Diseases. Cells. 2023; 12(14). PMC: 10377837. DOI: 10.3390/cells12141888. View

Prescott H, Harrison D, Rowan K, Shankar-Hari M, Wunsch H . Temporal Trends in Mortality of Critically Ill Patients with Sepsis in the United Kingdom, 1988-2019. Am J Respir Crit Care Med. 2024; 209(5):507-516. DOI: 10.1164/rccm.202309-1636OC. View

Wang L, Frey M, Kohli R . The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling. Front Endocrinol (Lausanne). 2022; 12:799648. PMC: 8804323. DOI: 10.3389/fendo.2021.799648. View

Hao H, Cao L, Jiang C, Che Y, Zhang S, Takahashi S . Farnesoid X Receptor Regulation of the NLRP3 Inflammasome Underlies Cholestasis-Associated Sepsis. Cell Metab. 2017; 25(4):856-867.e5. PMC: 6624427. DOI: 10.1016/j.cmet.2017.03.007. View

Li X, Lu W, Kharitonenkov A, Luo Y . Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases. J Intern Med. 2024; 295(3):292-312. DOI: 10.1111/joim.13767. View

Drexler S, Cai C, Hartmann A, Moch D, Gaitantzi H, Ney T . Intestinal BMP-9 locally upregulates FGF19 and is down-regulated in obese patients with diabetes. Mol Cell Endocrinol. 2023; 570:111934. DOI: 10.1016/j.mce.2023.111934. View

Heyland D, Ortiz A, Stoppe C, Patel J, Yeh D, Dukes G . Incidence, Risk Factors, and Clinical Consequence of Enteral Feeding Intolerance in the Mechanically Ventilated Critically Ill: An Analysis of a Multicenter, Multiyear Database. Crit Care Med. 2020; 49(1):49-59. DOI: 10.1097/CCM.0000000000004712. View

McClave S, Gualdoni J, Nagengast A, Marsano L, Bandy K, Martindale R . Gastrointestinal Dysfunction and Feeding Intolerance in Critical Illness: Do We Need an Objective Scoring System?. Curr Gastroenterol Rep. 2020; 22(1):1. DOI: 10.1007/s11894-019-0736-z. View

Schaap F, Van Der Gaag N, Gouma D, Jansen P . High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology. 2009; 49(4):1228-35. DOI: 10.1002/hep.22771. View

10.

Simbrunner B, Hofer B, Schwabl P, Zinober K, Petrenko O, Fuchs C . FXR-FGF19 signaling in the gut-liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence. Hepatol Int. 2024; 18(3):929-942. PMC: 11126514. DOI: 10.1007/s12072-023-10636-4. View

11.

Cosse C, Sabbagh C, Kamel S, Galmiche A, Regimbeau J . Procalcitonin and intestinal ischemia: a review of the literature. World J Gastroenterol. 2014; 20(47):17773-8. PMC: 4273127. DOI: 10.3748/wjg.v20.i47.17773. View

12.

Chapple L, Plummer M, Chapman M . Gut dysfunction in the ICU: diagnosis and management. Curr Opin Crit Care. 2021; 27(2):141-146. DOI: 10.1097/MCC.0000000000000813. View

13.

Strnad P, Tacke F, Koch A, Trautwein C . Liver - guardian, modifier and target of sepsis. Nat Rev Gastroenterol Hepatol. 2016; 14(1):55-66. DOI: 10.1038/nrgastro.2016.168. View

14.

Katafuchi T, Makishima M . Molecular Basis of Bile Acid-FXR-FGF15/19 Signaling Axis. Int J Mol Sci. 2022; 23(11). PMC: 9181207. DOI: 10.3390/ijms23116046. View

15.

Li X . The FGF metabolic axis. Front Med. 2019; 13(5):511-530. PMC: 7102389. DOI: 10.1007/s11684-019-0711-y. View

16.

Reintam Blaser A, Preiser J, Fruhwald S, Wilmer A, Wernerman J, Benstoem C . Gastrointestinal dysfunction in the critically ill: a systematic scoping review and research agenda proposed by the Section of Metabolism, Endocrinology and Nutrition of the European Society of Intensive Care Medicine. Crit Care. 2020; 24(1):224. PMC: 7226709. DOI: 10.1186/s13054-020-02889-4. View

17.

Lippi G, Sanchis-Gomar F . Procalcitonin in inflammatory bowel disease: Drawbacks and opportunities. World J Gastroenterol. 2018; 23(47):8283-8290. PMC: 5743499. DOI: 10.3748/wjg.v23.i47.8283. View

18.

Liu X, Wang Q, Yang D, Fu M, Yang M, Bi Y . Association between Gastrointestinal Dysfunction Score (GIDS) and disease severity and prognosis in critically ill patients: A prospective, observational study. Clin Nutr. 2023; 42(5):700-705. DOI: 10.1016/j.clnu.2023.03.004. View

19.

Singer M, Deutschman C, Seymour C, Shankar-Hari M, Annane D, Bauer M . The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315(8):801-10. PMC: 4968574. DOI: 10.1001/jama.2016.0287. View

20.

Avila M, Moschetta A . The FXR-FGF19 Gut-Liver Axis as a Novel "Hepatostat". Gastroenterology. 2015; 149(3):537-40. DOI: 10.1053/j.gastro.2015.07.029. View